4.10.23.2Vertical

COPD & Chronic Lung Disease Programs

Specialty programs managing COPD, emphysema, and chronic lung disease.

Market snapshot

These figures describe Pulmonology & Respiratory Medicine (4.10.23), the segment that COPD & Chronic Lung Disease Programs sits within — not COPD & Chronic Lung Disease Programs on its own.

FragmentationFragmentedEstimate

Within Offices of Physicians (NAICS 621111); the Census Bureau does not split physician offices by specialty, so pulmonology is not separately sized.

Business model & economics

Revenue model

Office, diagnostic, and procedure reimbursement

Key economics

Recurring revenue
Moderate

chronic respiratory care recurs

EBITDA margin
15–25%
Capex intensity
Low

Characteristics

  • Chronic respiratory disease and aging drive demand.
  • Sleep medicine and infusion as ancillaries.
  • Less consolidated, with emerging MSO interest.

M&A deal context

Deal activityModerate

Who’s acquiring

  • Emerging pulmonology MSO platforms
  • Multispecialty groups
  • Sleep- and infusion-aligned acquirers

What’s driving deals

  • Emerging pulmonology consolidation.
  • Chronic-respiratory and aging demand.
  • Ancillary sleep and infusion economics.

Find COPD & Chronic Lung Disease Programs acquisition targets

Search Acquisera’s index for companies classified under COPD & Chronic Lung Disease Programs (4.10.23.2) and build a targeted deal pipeline.

Search companies